Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This mechanistic trial compared the pharmacodynamics and safety of lixisenatide and liraglutide in combination with optimized insulin glargine with/without metformin in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration. The primary end point was change from baseline to week 8 in incremental area under the postprandial plasma glucose curve for 4 h after a standardized solid breakfast (AUC PPG0030–0430 h). Changes from baseline in gastric emptying, 24-h plasma glucose profile, HbA1c, fasting plasma glucose (FPG), 24-h ambulatory heart rate and blood pressure, amylase and lipase levels, and adverse events (AEs) were also assessed. RESULTS: In total, 142 patients were randomized and treated. Lixisenatide 20 µg achieved greater reductions of AUC PPG0030−0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, −6.0 [−7.8] h ⋅ mmol/L [−108.3 (−140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and −4.6 [−6.3] h ⋅ mmol/L [−83.0 (−114.2) h ⋅ mg/dL] vs. liraglutide 1.8 mg; P < 0.001 for both), and gastric emptying was delayed to a greater extent than with liraglutide 1.2 and 1.8 mg (P < 0.001 for treatment comparisons). FPG was unchanged in all treatment arms. At week 8, mean ± SD HbA1c was 6.2 ± 0.4% (44 ± 5 mmol/mol), 6.1 ± 0.3% (44 ± 4 mmol/mol), and 6.1 ± 0.3% (44 ± 4 mmol/mol) for lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg, respectively. At week 8, both liraglutide doses increased marginal mean ± SE 24-h heart rate from baseline by 9 ± 1 bpm vs. 3 ± 1 bpm with lixisenatide (P < 0.001). Occurrence of symptomatic hypoglycemia was higher with lixisenatide; gastrointestinal AEs were more common with liraglutide. Lipase levels were significantly increased from baseline with liraglutide 1.2 and 1.8 mg (marginal mean ± SE increase 21 ± 7 IU/L for both; P < 0.05). CONCLUSIONS: Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [51]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Ghoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell‐Jones, D., & Khan, R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 557
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Self-citationMonnier, L., Colette, C., Dunseath, G. J., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1612 · Cited by 490
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Timothy Garvey, W., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.cs · Cited by 280
Medication Taking and Diabetes
Odegard, P. S., & Capoccia, K. (2007) · The Diabetes Educator · doi:10.1177/0145721707308407 · Cited by 273
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationRiddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Self-citationEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
Self-citationAhrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Arnolds, S., Dellweg, S., Clair, J., Dain, M.-P., Nauck, M. A., Rave, K., & Kapitza, C. (2010) · Diabetes Care · doi:10.2337/dc09-2191 · Cited by 167
Self-citationLorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
Bonora, E., Corrao, G., Bagnardi, V., Ceriello, A., Comaschi, M., Montanari, P., & Meigs, J. B. (2006) · Diabetologia · doi:10.1007/s00125-006-0203-x · Cited by 141
Gill, A., Hoogwerf, B. J., Burger, J., Bruce, S., MacConell, L., Yan, P., Braun, D., Giaconia, J., & Malone, J. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-6 · Cited by 133
Owens, D. R., Luzio, S. D., Sert‐Langeron, C., & Riddle, M. C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01459.x · Cited by 99
Fonseca, V. A., DeVries, J. H., Henry, R. R., Donsmark, M., Thomsen, H. F., & Plutzky, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.009 · Cited by 98
Postchallenge Hyperglycemia in a National Sample of U.S. Adults With Type 2 Diabetes
Erlinger, T. P., & Brancati, F. L. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1734 · Cited by 83
Owens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Timely initiation of basal insulin
Riddle, M. C. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.003 · Cited by 74
Farrokhi, F., Klindukhova, O., Chandra, P., Peng, L., Smiley, D., Newton, C., Pasquel, F., Fereira, M. E., & Umpierrez, G. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600505 · Cited by 74
Exenatide therapy in insulin-treated type 2 diabetes and obesity
Nayak, U. A., Govindan, J., Baskar, V., Kalupahana, D., & Singh, B. M. (2010) · QJM · doi:10.1093/qjmed/hcq112 · Cited by 62
Rosenstock, J., Rodbard, H. W., Bain, S. C., D’Alessio, D., Seufert, J., Thomsen, A. B., Svendsen, C. B., & DeVries, J. H. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.008 · Cited by 46
Self-citationInsulin Therapy in Type 2 Diabetes Mellitus
Leahy, J. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.004 · Cited by 43
Plummer, M. P., Jones, K. L., Annink, C. E., Cousins, C. E., Meier, J. J., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Diabetes Care · doi:10.2337/dc13-1813 · Cited by 40
Self-citationMeneghini, L., Traylor, L., & Schwartz, S. L. (2010) · Endocrine Practice · doi:10.4158/ep09281.or · Cited by 33
The application of techniques using radionuclides to the study of gastric emptying.
Horowitz, M., Dj, C., Pj, C., Harding, P., & Shearman, D. J. C. (1982) · PubMed · Cited by 32
Bonafede, M., Kalsekar, A., Pawaskar, M. D., Ruiz, K. M., Torres, A., Kelly, K. R., & Curkendall, S. M. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-3 · Cited by 31
Liotta, L., Franco, A. D., Pazzagli, M., & Luconi, M. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6480-y · Cited by 10
Diamant, M., Nauck, M. A., Shaginian, R. M., Malone, J. K., Cleall, S., de Vries, D., Hoogwerf, B. J., MacConell, L., & Wolffenbuttel, B. H. R. (2013) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-013-0031-9 · Cited by 8
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“It has been claimed that short-acting GLP-1 RAs act preferentially on postmeal glycemic rises through their effect on gastric emptying, which are preserved over time [18,33,34], while there is substantial tachyphylaxis for long-acting compounds [18,34].”
BackgroundSelf-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Metadata
- Authors
- Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C.
- Affiliations
- St. Josef-Hospital (DE)
- Medical City Dallas Hospital (US)
- Sanofi (France) (FR)
- Profil Institute for Metabolic Research (DE)
- Profil, Mainz, Germany
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-17
- Volume
- 38
- Issue
- 7
- Pages
- 1263-1273
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2103274121
- Cited by
- 262
- References
- 50
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 21 · 2023: 18 · 2022: 7 · 2021: 18 · 2020: 23 · 2019: 26 · 2018: 27 · 2017: 38 · 2016: 39 · 2015: 17
- FWCI
- 34.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, liraglutide, type 2 diabetes, insulin glargine, metformin, postprandial glucose control, gastric emptying, incretin-based therapy, pharmacodynamics, HbA1c, fasting blood glucose, heart rate, blood pressure, amylase and lipase, drug safety, combination therapy, pharmacokinetics
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Gastric Emptying, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Treatment Outcome, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.